eligibility_summary
Adults 18–79 with resected PDAC (R0/1), pT1–3N0–2M0, CLDN18.2+, abnormal CA19‑9, post‑op + 3 mo adjuvant, ECOG 0–1, adequate organs, venous access, contraception. Exclude: prior neoadjuvant, borderline or recurrent/metastatic, ascites, CA19‑9 confounders, unresolved ≥G2 tox, pregnancy/lactation, active infections, immune-related conditions, bleeding risk, anticoagulant/antiplatelet, recent major surgery/trauma, prior gene‑modified cells, O2 ≤95%, CNS disease, recent live vaccine, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase Ib, open-label, single-arm study in resected pancreatic ductal adenocarcinoma after adjuvant chemotherapy. Intervention: CT041 autologous CAR T-cell injection (cell therapy, patient-derived T cells genetically engineered to express a chimeric antigen receptor). Mechanism of action: The CAR specifically recognizes Claudin18.2 (CLDN18.2) on tumor cells, binding triggers CAR signaling to activate and expand T cells, leading to targeted cytotoxicity and cytokine-mediated killing of CLDN18.2-positive cancer cells. Dosing: up to three infusions. Targets: CLDN18.2, a tight-junction claudin isoform overexpressed on pancreatic cancer cells, engages T-cell effector pathways to eradicate residual CLDN18.2+ disease.